Ozempic Australia: A Guide to Access, Cost, Safety, and Weight Management

Ozempic (semaglutide) is a PBS-subsidised prescription medication approved in Australia for type 2 diabetes, and is increasingly prescribed off-label for weight loss. Whether it is right for you depends on your medical history, clinical eligibility, and how it fits into a broader approach to metabolic health.

For a broader picture of your metabolic health before or during treatment, Everlab's comprehensive assessment gives you and your doctor measurable data to work from, including markers relevant to weight and metabolic health.

‍

Disclaimer: This article is for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. It is not an endorsement of Ozempic or any GLP-1 medication for weight loss. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.

Ozempic Semaglutide: What it Is and How GLP-1 Works

Ozempic is a brand name for semaglutide. Glucagon-like peptide 1 is a hormone naturally produced in the gut after you eat. It signals the pancreas to release insulin, slows the emptying of the stomach, and reduces appetite by affecting brain regions that control hunger and satiety.

Ozempic semaglutide acts by mimicking this natural hormone. When injected once weekly using a pre-filled pen, it triggers effects that help manage blood sugar and weight:

• Enhancing insulin secretion in response to meals.
• Lowering glucagon to help with diabetes control.
• Increasing feelings of fullness to help you lose weight.
• Decreasing appetite to help reduce calorie intake.

The active ingredient in Ozempic is the same as that in Wegovy, a medication from the Danish pharmaceutical company Novo Nordisk. However, they are marketed for different purposes and come in varying dose ranges.

What “Off Label” Means for Weight Loss

In Australia, the TGA has approved Ozempic for type 2 diabetes, but it is not officially authorised as one of the primary weight loss drugs. However, doctors can legally provide a private prescription for obesity management if it is clinically appropriate. This is known as being prescribed off-label.

Because it is off-label for weight loss, it is not covered by the PBS. This requires patients to pay the full price for a private prescription. The RACGP has advocated for semaglutide to be included on the PBS for chronic weight management to reduce health inequity, as approximately 32% of Australian adults live with obesity.

How Available is Ozempic in Australia?

This medication is available by prescription only. While 2024 saw significant supply issues, the TGA officially removed semaglutide from the major medicine shortage list in July 2025, and supply has remained stable into 2026.

A new 3 mL pre-filled pen has now replaced the older 1.5 mL version. This updated presentation delivers the same prescribed dose but features a different device design. Patients should note that while the pen looks slightly different, the active ingredient and the number of doses remain identical. Always check your device for damage and ensure it matches your current medical orders.

As of October 2024, the TGA officially banned the production of compounded replicas of these medications due to safety concerns. This means that pharmacies are no longer permitted to manufacture copycat versions of semaglutide. Furthermore, it is illegal to purchase such medications online without a valid Australian prescription due to concerns over counterfeit products. These unregulated items often lack the active ingredient or contain harmful substances, posing serious health risks.

Who Qualifies for Pharmaceutical Benefits Scheme Support?

The Pharmaceutical Benefits Scheme subsidises medicines for eligible patients. For those with type 2 diabetes, the cost is now $25 for Medicare cardholders and $7.70 for concession card holders as of January 2026. If you are using it for weight loss, these subsidies do not apply.

Ozempic for Weight Loss: Evidence and Expectations

In the STEP 1 trial, participants using the 2.4 mg maintenance dose of semaglutide for chronic weight management lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. Weight loss with semaglutide is dose-dependent: trials in people with type 2 diabetes using lower doses (1 mg weekly) showed smaller average weight loss (around 6–10%), reflecting both the lower dose and the effect of diabetes itself on weight response.

For those looking to lose weight, realistic expectations are vital. Clinical guidelines state that Ozempic must be used alongside diet, exercise, and other diabetes medications when needed for effective management. The medication works best alongside healthy eating, regular physical activity, and psychological support. Doctors typically consider weight loss options for patients with a body mass index (BMI) of 30 or above, or 27 if they have weight-related health conditions like heart disease or pre-diabetes.

Medication works best as part of a broader approach. Pairing treatment with structured nutrition, physical activity, and metabolic monitoring supports more sustainable outcomes.

Who Should Not Use GLP-1 Receptor Agonists?

Not all individuals are suitable candidates for semaglutide or other GLP-1 receptor agonists. Your healthcare provider will conduct a thorough review of your medical history to ensure any treatment is safe for you.

Clinical considerations that may prevent the use of these medications include:

• Specific Medical Histories: This class of medication is generally not suitable for individuals with a history of pancreatitis or diabetic ketoacidosis.
• Genetic Risks: They are contraindicated for those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Chronic Health Cautions: Your doctor will carefully assess the risks if you have a history of complex cardiovascular issues or significant renal (kidney) conditions, particularly where there is a risk of dehydration.
• Pregnancy and Breastfeeding: Semaglutide is not recommended for use during pregnancy or while breastfeeding. If you are planning a pregnancy, your doctor will usually advise a washout period before conception.

Always consult a qualified medical practitioner to investigate the treatment options that are most appropriate for your clinical profile.

What are the Common Side Effects of Ozempic and Safety Precautions?

The common side effects of semaglutide include nausea, vomiting, diarrhoea, and stomach pain. These are usually most noticeable when you first start the treatment or increase the dose. If you are prescribed a GLP-1 receptor agonist, your doctor will discuss how to manage common gastrointestinal symptoms. Below are general strategies that may assist:

• Adjust Your Eating Habits: To help manage nausea or discomfort, consider eating smaller meals, avoiding high-fat or greasy foods, and staying well-hydrated. These adjustments are often recommended to help ease discomfort.
• Seek Professional Guidance: If side effects are persistent or severe, consult your GP or specialist. They may discuss adjusting your titration schedule to improve tolerance.
• Monitor for Adverse Effects: It is essential to monitor for fluctuations in blood sugar levels, especially if you are using other medications for diabetes control. Your healthcare provider will likely schedule regular blood tests to track your kidney function and metabolic health.
• Recognise Severe Symptoms: If you experience severe abdominal pain that does not subside, persistent vomiting, or signs of pancreatitis, seek medical attention immediately. While rare, serious side effects require urgent clinical assessment.

Comparing Weight Loss Medications in Australia

When looking at weight loss drugs, it is important to understand the different options available.

Novo Nordisk has discontinued Saxenda in Australia as of late 2025. While weight loss is the goal for many, selecting the right medication is a clinical decision among several weight loss drugs.

Why Routine Check-Ups May Not Be Enough

Routine diabetes checks typically focus on blood glucose and lipid levels.

Advanced biomarker panels can provide a broader picture of metabolic health, including markers like insulin resistance indicators, lipid subfractions, and inflammatory signals, which may not be captured in standard screening.

This additional context can support more informed conversations with your doctor.

How Advanced Biomarker Testing Can Help You Make Better Medication Decisions

Advanced biomarker testing is useful when standard care doesn’t fully explain ongoing symptoms or metabolic issues. This type of testing looks at a wider range of markers, such as:

• Metabolic Health Indicators
• Inflammatory Signals
• Thyroid Antibodies
• Lipid Subfractions
• Insulin Markers
• Other System-Level Clues

These markers are important for managing diabetes, weight, and cardiovascular health. Everlab tests over 100 biomarkers to find patterns that routine tests may not spot. This additional context supports more informed discussions between you and your healthcare provider when reviewing treatment direction.

For people using Ozempic, broader biomarker testing can track how the medication affects key metabolic markers over time, supporting treatment review and long-term health monitoring.

When Should You Speak to a Healthcare Professional?

If you are using Ozempic or similar medications, request immediate medical care if you develop:

• Severe or persistent stomach pain, especially if it is worsening
• Repeated vomiting with inability to keep fluids down
• Symptoms of dehydration, such as dizziness, fainting, or very little urine
• Signs of a severe allergic reaction, such as swelling of the face or throat
• Severe weakness or symptoms that are rapidly escalating
• Concerning diabetes symptoms when unwell, particularly if you cannot eat or drink.

What Can I Take Instead of Ozempic (Semaglutide) in Australia?

If you are considering alternatives to your current metabolic treatment, there are different clinical pathways available in Australia. Because these are all prescription-only (Schedule 4) medications, any change must be managed by your healthcare provider, taking into account your clinical history and relevant test results.

1. Other GLP-1 Receptor Agonists

This family of medications mimics a natural hormone to regulate appetite and blood sugar. They include:

• Dulaglutide: A weekly injection primarily prescribed and PBS-subsidised for type 2 diabetes.
• Liraglutide: Previously a common daily option. Note that as of late 2025, some original brands such as Victoza have been discontinued in Australia, though the active ingredient may remain available in other formulations for weight management.

2. Dual-Action GIP/GLP-1 Medications

A newer clinical option is tirzepatide. Unlike medications that target one hormone, this targets two, which may lead to different metabolic outcomes. In 2026, this is TGA-approved for both diabetes and chronic weight management, though it is usually accessed via private prescription.

3. SGLT2 Inhibitors

Medications like empagliflozin and dapagliflozin work through the kidneys rather than the gut. They help the body remove excess glucose through urine. While their primary use is for diabetes and heart health, they are often used in combination with other treatments to support overall metabolic balance.

4. Metformin

Often the first-line treatment for metabolic health in Australia, metformin is a reliable oral tablet that helps your body use insulin more effectively. It is widely available and subsidised on the PBS for eligible patients.

5. Non-Hormonal Weight Management

For those focusing strictly on weight loss, your doctor might suggest options that don't involve GLP-1 hormones:

• Naltrexone/Bupropion: A combination therapy that targets the reward centres of the brain to reduce cravings.
• Phentermine: A short-term oral treatment used to suppress appetite under strict medical supervision.

6. Lifestyle and Biomarker Support

No medication works in a vacuum. A commonly recommended approach in Australia involves pairing prescriptions with:

• Structured Nutrition: Ensuring you maintain lean muscle mass while losing weight.
• Advanced Monitoring: Using services like Everlab to track markers like HOMA-IR (insulin resistance) and ApoB (a key lipid subfraction).

Conclusion

Ozempic can be beneficial for managing type 2 diabetes in Australia and may help some people lose weight. However, the decision to use it depends on approvals, PBS rules, availability, and individual safety. A helpful discussion with your GP should include your health goals, medical history, current medications, affordability, and how you will be monitored for any risks.

If you want to have a clearer conversation and follow-up plan, Everlab provides comprehensive biomarker testing to support informed conversations with your GP or specialist about your treatment options.

‍

Disclaimer: This content is intended for general informational purposes only and does not constitute medical advice. Nothing in this article should be construed as an endorsement of Ozempic or any weight management medication. Prescribing decisions are made exclusively by qualified medical practitioners based on individual clinical assessment.

References:

• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F., for the STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
• Australian Institute of Health and Welfare. (2025). Overweight and obesity [Web report]. AIHW, Australian Government.
• Wilding et al. (2021), NEJM. STEP 2 trial data (semaglutide in adults with type 2 diabetes and overweight/obesity).